Bionter aims to innovate particle testing. Its first product is a particle counter that is fully automated and allows non-destructive sample testing.
Bionter has raised €2.9M across 1 funding round from 1 investor, most recently a Seed round in Apr 2022. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-04-28 | Seed | €2.9M |
| Dynamk Capital |
| View deal → |
